China IVF Market is forecasted to be priced at around US$ 9.04 Billion by 2030. China is undergoing a significant population decline and is taking urgent measures to deal with it. As a strategy for this problem, China might plan to liberalize in-vitro fertility (IVF) remedy centers. This move is anticipated to boost demand for fertility remedies across the country. IVF is a go-to method for couples experiencing fertility troubles and looking to have a biological infant. It includes a specific process presented by specialized clinics and has proven surprisingly successful.
The increasing age of first-time mothers contributes considerably to the rise of the China IVF market. Delayed motherhood is associated with higher infertility rates, propelling the demand for assisted reproductive technology like IVF. As more women face challenges conceiving, obviously because of age-associated factors, they turn to IVF for fertility assistance. This trend underscores the significance of IVF in addressing the desires of older mothers and propelling the enlargement of the fertility market in China. So, the China In-Vitro Fertilization (IVF) Market was US$ 5.37 Billion in 2023.
China has promised to construct at least one establishment offering In Vitro Fertilization (I.V.F.) for every 2.3 to 3 million people by 2025. Currently, 539 medical organizations and 27 sperm banks have agreed to carry out helped reproductive technology. Each year, these facilities deliver more than a million cycles of I.V.F. and other assisted fertility services, resulting in about 300,000 babies being conceived. These measures are effective practices to help couples who want to have children. If China can cost-effectively deliver the services, it could be an instance for other nations encountering similar infertility challenges.
Donor eggs are becoming increasingly popular in China for in vitro fertilization (IVF)
By treatment types, the China IVF Market is fragmented into Fresh Embryo, Frozen Embryo, Donor Egg, and Others. Donor egg is poised to be among the few reasonably sought-after treatments in the China In-Vitro Fertilization (IVF) market. This is because of increasing maternal age and declining fertility rates. With superior age linked to diminished egg quality and higher infertility rates, couples opt for donor eggs to enhance their possibilities of conception. Moreover, cultural norms emphasizing biological offspring and societal expectations for parenthood drive the demand for donor egg remedies, making it a distinguished preference within the China IVF market.
The report titled “China IVF Market By Treatment types (Fresh Embryo, Frozen Embryo, Donor Egg, and Others), Instrument (Culture Media, Disposable Devices, and Capital Equipment), Procedure(ICSI IVF, Non-ICSI IVF, and IUI Canada),End-User (Fertility Clinics, Hospitals, and Others) Company Analysis (Vitrolife, Cloudnine, Nova IVI Fertility, Monash IVF, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono, Inc.)” provides a complete study of the China In-Vitro Fertilization (IVF) Industry.
2. Frozen Embryo
3. Donor Egg
4. Others
2. Disposable Devices
3. Capital Equipment
2. Non-ICSI IVF
3. IUI Canada
2. Hospitals
3. Others
2. Cloudnine
3. Nova IVI Fertility
4. Monash IVF
5. Maria Fertility Hospital
6. Bangkok Fertility Center
7. EMD Serono, Inc.
China IVF Market is anticipated to grow at a CAGR of 7.72% from 2024 to 2030
Economic improvement has fueled a terrific increase in the China in-vitro Fertilization (IVF) market. Rising affluence has led to lifestyle modifications, along with delayed childbearing and expanded infertility rates because of age-associated elements. As a result, the need for fertility remedies like IVF has surged. Moreover, improved healthcare infrastructure and rising consciousness about infertility treatments have made IVF extra accessible. With a growing middle class and authorities' help with reproductive fitness services, Chinese economic prosperity continues to force the growth of the IVF market in China.The increasing age of first-time mothers contributes considerably to the rise of the China IVF market. Delayed motherhood is associated with higher infertility rates, propelling the demand for assisted reproductive technology like IVF. As more women face challenges conceiving, obviously because of age-associated factors, they turn to IVF for fertility assistance. This trend underscores the significance of IVF in addressing the desires of older mothers and propelling the enlargement of the fertility market in China. So, the China In-Vitro Fertilization (IVF) Market was US$ 5.37 Billion in 2023.
China has promised to construct at least one establishment offering In Vitro Fertilization (I.V.F.) for every 2.3 to 3 million people by 2025. Currently, 539 medical organizations and 27 sperm banks have agreed to carry out helped reproductive technology. Each year, these facilities deliver more than a million cycles of I.V.F. and other assisted fertility services, resulting in about 300,000 babies being conceived. These measures are effective practices to help couples who want to have children. If China can cost-effectively deliver the services, it could be an instance for other nations encountering similar infertility challenges.
Donor eggs are becoming increasingly popular in China for in vitro fertilization (IVF)
By treatment types, the China IVF Market is fragmented into Fresh Embryo, Frozen Embryo, Donor Egg, and Others. Donor egg is poised to be among the few reasonably sought-after treatments in the China In-Vitro Fertilization (IVF) market. This is because of increasing maternal age and declining fertility rates. With superior age linked to diminished egg quality and higher infertility rates, couples opt for donor eggs to enhance their possibilities of conception. Moreover, cultural norms emphasizing biological offspring and societal expectations for parenthood drive the demand for donor egg remedies, making it a distinguished preference within the China IVF market.
It is possible that disposable devices are being widely used in the IVF market in China
By instrument, the China IVF Market is segmented into Culture Media, Disposable Devices, and Capital Equipment. Disposable devices are predicted to be among the instruments used considerably in the China In-Vitro Fertilization (IVF) market. This is due to the heightened consciousness of infection control, stringent hygiene requirements, and the benefit of one-time use. Using disposable contraptions eliminates the need for sterilization, saving time and aids. Furthermore, the elevated use of disposable devices aligns with the developing emphasis on patient safety and contamination prevention in healthcare settings. Therefore, professionals in the China IVF market can effectively utilize disposable devices.ICSI IVF is expected to be one of the most widely used methods in the China In-Vitro Fertilization (IVF) market
By procedure, the China IVF Market is categorised into ICSI IVF, Non-ICSI IVF, and IUI Canada. ICSI IVF is foreseen to be among the considerably utilized processes in the China In-Vitro Fertilization (IVF) market. This is due to its effectiveness in addressing male infertility problems. With a rising prevalence of male aspect infertility and elevated awareness about assisted reproductive technologies, ICSI IVF gives a promising solution. This system involves the direct injection of a single sperm into an egg, bypassing natural limitations to fertilization. As demand for fertility remedies grows and couples seek answers to conception challenges, ICSI IVF emerges as a favored option, expediting its extensive use in the in-vitro fertilization market.China IVF market might see a notable rise in the use of fertility clinics
By end-user, the China In-Vitro Fertilization (IVF) Market is divided into Fertility Clinics, Hospitals, and Others. Fertility clinics are projected to experience a considerable increase in utilization in the China In-Vitro Fertilization (IVF) market. The factors for growth encompass rising infertility rates, growing attention to fertility treatments, and improvements in reproductive technology. As more couples are trying to find specialized care and customized treatment plans to cope with their fertility issues, the demand for offerings provided by fertility clinics is predicted to surge. Consequently, fertility clinics are poised to develop customers within the IVF market substantially.Key Players
The leading businesses in the China in-vitro fertilization (IVF) market are Vitrolife, Cloudnine, Nova IVI Fertility, Monash IVF, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono, Inc.The report titled “China IVF Market By Treatment types (Fresh Embryo, Frozen Embryo, Donor Egg, and Others), Instrument (Culture Media, Disposable Devices, and Capital Equipment), Procedure(ICSI IVF, Non-ICSI IVF, and IUI Canada),End-User (Fertility Clinics, Hospitals, and Others) Company Analysis (Vitrolife, Cloudnine, Nova IVI Fertility, Monash IVF, Maria Fertility Hospital, Bangkok Fertility Center, and EMD Serono, Inc.)” provides a complete study of the China In-Vitro Fertilization (IVF) Industry.
Treatment Types - China In-Vitro Fertilization (IVF) Market breakup in 4 viewpoints:
1. Fresh Embryo2. Frozen Embryo
3. Donor Egg
4. Others
Instrument - China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
1. Culture Media2. Disposable Devices
3. Capital Equipment
Procedure - China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
1. ICSI IVF2. Non-ICSI IVF
3. IUI Canada
End-User - China In-Vitro Fertilization (IVF) Market breakup in 3 viewpoints:
1. Fertility Clinics2. Hospitals
3. Others
All the Key players have been covered from 3 Viewpoints:
- Overview
- Recent Development
- Revenue Analysis
Company Analysis:
1. Vitrolife2. Cloudnine
3. Nova IVI Fertility
4. Monash IVF
5. Maria Fertility Hospital
6. Bangkok Fertility Center
7. EMD Serono, Inc.
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary5. China In-Vitro Fertilization Market
4. Market Dynamics
6. Market Share - China In-Vitro Fertilization
7. Treatment Types - China In-Vitro Fertilization Market
8. Instrument - China In-Vitro Fertilization Market
9. Procedure - China In-Vitro Fertilization Market
10. End User - China In-Vitro Fertilization Market
11. Porter’s Five Forces - China In-Vitro Fertilization Market
12. SWOT Analysis - China In-Vitro Fertilization Market
13. Key Players Analysis
List of Figures
List of Tables
Companies Mentioned
- Vitrolife
- Cloudnine
- Nova IVI Fertility
- Monash IVF
- Maria Fertility Hospital
- Bangkok Fertility Center
- EMD Serono, Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 105 |
| Published | February 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 5.37 Billion |
| Forecasted Market Value ( USD | $ 9.04 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | China |
| No. of Companies Mentioned | 7 |
